ArticleCerebral cortex (New York, N.Y. : 1991)2017
A Leptin Fragment Mirrors the Cognitive Enhancing and Neuroprotective Actions of Leptin.
Article in Cerebral cortex (New York, N.Y. : 1991), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Amyloid pathology and modifiable risk factors in cognitive decline among cognitively unimpaired older adults.The journal of prevention of Alzheimer's disease · 2026Article
- Obesity-induced cognitive impairment: Underlying mechanisms and therapeutic prospects.Metabolism open · 2026Review
- The leptin fragment Lep116-130 attenuates hedonic consumption and sucrose-seeking in mice.Frontiers in pharmacology · 2026Article
- Therapeutic Potential of Leptin in Neurodegenerative Disease.Biomedicines · 2025Review
- Brain-Bone Axis in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
- Causal links between obesity, lipids, adipokines, and cognition: a bidirectional Mendelian-randomization analysis.Frontiers in endocrinology · 2025Article
- Targeting Metabolic Dysregulation in Alzheimer's Disease: A Potential Therapeutic Strategy.Current drug metabolism · 2025Review
- Obesity paradox in cognitive function: a longitudinal study of BMI and cognitive impairment in older adult Chinese population.Frontiers in aging neuroscience · 2025Article
- Hippocampal Leptin Resistance and Cognitive Decline: Mechanisms, Therapeutic Strategies and Clinical Implications.Biomedicines · 2024Review
- Novel Leptin-Based Therapeutic Strategies to Limit Synaptic Dysfunction in Alzheimer's Disease.International journal of molecular sciences · 2024Review
- G-protein coupled estrogen receptor (GPER1) activation promotes synaptic insertion of AMPA receptors and induction of chemical LTP at hippocampal temporoammonic-CA1 synapses.Molecular brain · 2023Article
- Food for Thought: Leptin and Hippocampal Synaptic Function.Frontiers in pharmacology · 2022Review
- Harnessing the Power of Leptin: The Biochemical Link Connecting Obesity, Diabetes, and Cognitive Decline.Frontiers in aging neuroscience · 2022Review
- Long-term culture of SH-SY5Y neuroblastoma cells in the absence of neurotrophins: A novel model of neuronal ageing.Journal of neuroscience methods · 2021Article
- The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.Nature reviews. Drug discovery · 2020Review
- Adipocytokines: Are they the Theory of Everything?Cytokine · 2020Review
- Insulin Modulates Excitatory Synaptic Transmission and Synaptic Plasticity in the Mouse Hippocampus.Neuroscience · 2019Article
- Leptin Regulation of Synaptic Function at Hippocampal TA-CA1 and SC-CA1 Synapses: Implications for Health and Disease.Neurochemical research · 2019Review
- Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus.Frontiers in molecular neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A key pathology of Alzheimer's disease (AD) is amyloid β (Aβ) accumulation that triggers synaptic impairments and neuronal death. Metabolic disruption is common in AD and recent evidence implicates impaired leptin function in AD. Thus the leptin system may be a novel therapeutic target in AD. Indeed, leptin has cognitive enhancing properties and it prevents the aberrant effects of Aβ on hippocampal synaptic function and neuronal viability. However, as leptin is a large peptide, development of smaller leptin-mimetics may be the best therapeutic approach. Thus, we have examined the cognitive enhancing and neuroprotective properties of known bioactive leptin fragments. Here we show that the leptin (116-130) fragment, but not leptin (22-56), mirrored the ability of leptin to promote AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Administration of leptin (116-130) also mirrored the cognitive enhancing effects of leptin as it enhanced performance in episodic-like memory tests. Moreover, leptin (116-130) prevented hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. These findings establish further the importance of the leptin system as a therapeutic target in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.